Mutual of America Capital Management LLC Grows Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Mutual of America Capital Management LLC boosted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 8.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 349,688 shares of the company's stock after purchasing an additional 27,480 shares during the quarter. Mutual of America Capital Management LLC's holdings in Kenvue were worth $7,466,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Flputnam Investment Management Co. grew its stake in shares of Kenvue by 9.1% in the fourth quarter. Flputnam Investment Management Co. now owns 62,622 shares of the company's stock worth $1,337,000 after acquiring an additional 5,213 shares during the last quarter. Dynasty Wealth Management LLC boosted its stake in Kenvue by 30.5% in the 4th quarter. Dynasty Wealth Management LLC now owns 54,589 shares of the company's stock worth $1,165,000 after purchasing an additional 12,759 shares in the last quarter. CORDA Investment Management LLC. grew its position in Kenvue by 1.4% during the 4th quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock valued at $26,754,000 after purchasing an additional 17,466 shares during the last quarter. QRG Capital Management Inc. bought a new stake in Kenvue during the 4th quarter valued at about $218,000. Finally, Versor Investments LP bought a new stake in Kenvue during the 4th quarter valued at about $333,000. Institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

KVUE has been the topic of several analyst reports. Barclays cut their price target on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a report on Friday, January 17th. Citigroup cut their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 15th. Canaccord Genuity Group decreased their price target on Kenvue from $27.00 to $24.00 and set a "buy" rating for the company in a research note on Friday, February 7th. UBS Group dropped their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Finally, Piper Sandler boosted their target price on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $23.33.

Kenvue Stock Performance

KVUE stock traded down $0.36 during midday trading on Tuesday, reaching $23.44. 15,368,134 shares of the company's stock traded hands, compared to its average volume of 14,603,316. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The stock has a market cap of $44.79 billion, a P/E ratio of 44.22, a PEG ratio of 2.62 and a beta of 1.45. The stock's 50-day moving average is $21.54 and its 200 day moving average is $22.30.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.